LT3626729T - Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį - Google Patents

Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį

Info

Publication number
LT3626729T
LT3626729T LTEP19199101.7T LT19199101T LT3626729T LT 3626729 T LT3626729 T LT 3626729T LT 19199101 T LT19199101 T LT 19199101T LT 3626729 T LT3626729 T LT 3626729T
Authority
LT
Lithuania
Prior art keywords
peptides
hcc
cancers
combination
hepatocellular carcinoma
Prior art date
Application number
LTEP19199101.7T
Other languages
English (en)
Inventor
Toni Weinschenk
Andrea Mahr
Jens Fritsche
Phillip Müller
Anita WIEBE
Sarah MISSEL
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1501017.6A external-priority patent/GB201501017D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of LT3626729T publication Critical patent/LT3626729T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
LTEP19199101.7T 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį LT3626729T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096165P 2014-12-23 2014-12-23
GB201423016 2014-12-23
GBGB1501017.6A GB201501017D0 (en) 2014-12-23 2015-01-21 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Publications (1)

Publication Number Publication Date
LT3626729T true LT3626729T (lt) 2021-10-25

Family

ID=66846825

Family Applications (5)

Application Number Title Priority Date Filing Date
LTEP19199101.7T LT3626729T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP19199098.5T LT3616706T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP15813809.9T LT3236985T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP19199125.6T LT3626731T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP19170191.1T LT3545965T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį

Family Applications After (4)

Application Number Title Priority Date Filing Date
LTEP19199098.5T LT3616706T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP15813809.9T LT3236985T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP19199125.6T LT3626731T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį
LTEP19170191.1T LT3545965T (lt) 2014-12-23 2015-12-16 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį

Country Status (28)

Country Link
US (9) US20220016227A1 (lt)
JP (8) JP7358299B2 (lt)
KR (4) KR102643923B1 (lt)
AU (1) AU2022268329A1 (lt)
CL (1) CL2021001479A1 (lt)
CO (1) CO2017003772A2 (lt)
CR (1) CR20210289A (lt)
CY (5) CY1122491T1 (lt)
DK (1) DK3236985T4 (lt)
ES (5) ES2887107T3 (lt)
FI (1) FI3236985T4 (lt)
HR (5) HRP20211327T1 (lt)
HU (5) HUE057014T2 (lt)
IL (1) IL281752A (lt)
LT (5) LT3626729T (lt)
MA (6) MA50819A (lt)
MD (5) MD3626729T2 (lt)
MX (6) MX2020011793A (lt)
MY (1) MY178137A (lt)
PE (1) PE20211740A1 (lt)
PL (4) PL3626731T3 (lt)
PT (5) PT3545965T (lt)
RS (1) RS62575B1 (lt)
SG (2) SG10202102698VA (lt)
SI (2) SI3626731T1 (lt)
TW (3) TW202321273A (lt)
UA (1) UA124331C2 (lt)
ZA (1) ZA201701762B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057014T2 (hu) * 2014-12-23 2022-04-28 Immatics Biotechnologies Gmbh Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (hcc) és más rákok elleni immunoterápiában történõ alkalmazásra
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2061201A (en) 1999-12-17 2001-06-25 Chiron Corporation Mammalian dishevelled-associated proteins
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
AU2001276018A1 (en) 2000-07-20 2002-02-05 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
TW200413406A (en) * 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
EP1581812B1 (en) 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
CA2690627C (en) * 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
WO2009026547A1 (en) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Methods of assaying vaccine potency
DK2201100T3 (en) 2007-09-14 2016-05-30 Univ Bruxelles IMPROVING THE T-CELL STIMULATING ABILITY OF HUMAN antigen presenting cells AND USE THEREOF IN THE VACCINATION
EP2262834A4 (en) 2008-02-27 2011-08-17 Receptor Logic Inc ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME
WO2009151487A1 (en) 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US10262103B2 (en) * 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
CN102939536A (zh) 2009-11-14 2013-02-20 匡-宇·邱 用于治疗和/或预防动脉粥样硬化的免疫调节方法和***
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
AU2011336997A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
RU2013126888A (ru) * 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100
CA2817538A1 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
CN104093830A (zh) * 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013070603A1 (en) 2011-11-11 2013-05-16 Cedars-Sinai Medical Center Compositions and methods for treatment of kidney diseases
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
CA2883673A1 (en) * 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB201301632D0 (en) 2013-01-30 2013-03-13 Imp Innovations Complement System
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
CN103739667B (zh) 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
WO2015136072A1 (en) 2014-03-14 2015-09-17 Immunocore Limited Tcr libraries
HUE057014T2 (hu) * 2014-12-23 2022-04-28 Immatics Biotechnologies Gmbh Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (hcc) és más rákok elleni immunoterápiában történõ alkalmazásra
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
CN110023330B (zh) 2016-04-08 2023-12-12 艾达普特免疫有限公司 T细胞受体
CN109476724B (zh) 2016-04-08 2023-04-04 艾达普特免疫有限公司 T细胞受体
EP3988565A1 (en) 2016-04-08 2022-04-27 Adaptimmune Limited T cell receptors
RU2735726C2 (ru) 2016-07-27 2020-11-06 Шарп Кабусики Кайся Способы и устройство беспроводной связи с использованием тега значения системной информации
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
CN110809580A (zh) 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
BR112019025667A2 (pt) 2017-06-05 2020-09-01 Mie University proteína de ligação ao antígeno que reconhece o peptídeo derivado de mage-a4
KR20200024905A (ko) 2017-07-04 2020-03-09 큐어백 아게 신규 핵산 분자
CN111328288A (zh) 2017-08-18 2020-06-23 磨石肿瘤生物技术公司 靶向共同抗原的抗原结合蛋白
JP7382310B2 (ja) 2017-09-06 2023-11-16 カリフォルニア インスティチュート オブ テクノロジー シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ）
TWI837109B (zh) 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
KR20210003767A (ko) 2018-04-19 2021-01-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
KR20210013105A (ko) 2018-05-23 2021-02-03 그릿스톤 온콜로지, 인코포레이티드 공유 항원
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
MA46913B1 (fr) 2021-09-30
US20220054613A1 (en) 2022-02-24
PE20211740A1 (es) 2021-09-06
PT3616706T (pt) 2021-11-23
HUE057014T2 (hu) 2022-04-28
ES2900106T3 (es) 2022-03-15
HUE056607T2 (hu) 2022-02-28
JP7109801B2 (ja) 2022-08-01
KR102395995B1 (ko) 2022-05-09
US20220023403A1 (en) 2022-01-27
US11559573B2 (en) 2023-01-24
PT3626731T (pt) 2021-11-29
MA49156A (fr) 2020-03-25
LT3236985T (lt) 2019-12-27
MD3236985T3 (ro) 2023-03-31
TW202321273A (zh) 2023-06-01
KR102435015B1 (ko) 2022-08-22
SI3626731T1 (sl) 2021-12-31
PT3626729T (pt) 2021-11-03
US11576956B2 (en) 2023-02-14
MD3236985T2 (ro) 2020-02-29
PL3626731T3 (pl) 2022-05-02
HRP20211753T1 (hr) 2022-04-01
SG10202101444UA (en) 2021-03-30
HUE046641T2 (hu) 2020-03-30
HRP20211754T1 (hr) 2022-03-04
JP2020191864A (ja) 2020-12-03
PL3545965T3 (pl) 2021-12-27
US20220354939A1 (en) 2022-11-10
KR20220118565A (ko) 2022-08-25
CO2017003772A2 (es) 2017-09-20
MD3626729T2 (ro) 2021-12-31
MX2020011787A (es) 2020-11-24
DK3236985T3 (da) 2020-01-20
US11779638B2 (en) 2023-10-10
US20220031824A1 (en) 2022-02-03
MA48487B1 (fr) 2021-11-30
US20220339272A1 (en) 2022-10-27
UA124331C2 (uk) 2021-09-01
CY1124533T1 (el) 2022-07-22
US20220118071A1 (en) 2022-04-21
MA50819A (fr) 2021-04-07
PT3545965T (pt) 2021-09-20
TW202124426A (zh) 2021-07-01
ES2899425T3 (es) 2022-03-11
LT3545965T (lt) 2021-09-10
US11679147B2 (en) 2023-06-20
MX2020005188A (es) 2020-08-20
MA49155B1 (fr) 2021-11-30
JP2020191868A (ja) 2020-12-03
HRP20192212T4 (hr) 2022-11-25
IL281752A (en) 2021-05-31
JP2020191867A (ja) 2020-12-03
FI3236985T4 (fi) 2022-12-15
MX2020011791A (es) 2020-11-24
JP2020191869A (ja) 2020-12-03
PT3236985T (pt) 2020-01-22
TWI754892B (zh) 2022-02-11
MX2020004757A (es) 2020-08-20
JP7026411B2 (ja) 2022-02-28
JP7358299B2 (ja) 2023-10-10
CR20210289A (es) 2021-06-30
CY1124813T1 (el) 2022-11-25
LT3616706T (lt) 2022-02-10
MA48487A (fr) 2020-03-04
RS62575B1 (sr) 2021-12-31
MA46913A (fr) 2021-03-24
HUE055489T2 (hu) 2021-11-29
JP2023100927A (ja) 2023-07-19
KR102643923B1 (ko) 2024-03-05
TW202028231A (zh) 2020-08-01
US20220023404A1 (en) 2022-01-27
US20220257739A1 (en) 2022-08-18
CY1124847T1 (el) 2022-11-25
MD3545965T2 (ro) 2021-10-31
KR20200066382A (ko) 2020-06-09
MA49157A (fr) 2021-06-02
ES2763911T5 (es) 2023-01-05
KR20200123269A (ko) 2020-10-28
MD3626731T2 (ro) 2022-01-31
KR20240033128A (ko) 2024-03-12
DK3236985T4 (da) 2022-11-28
HRP20211327T1 (hr) 2022-01-21
ES2896919T3 (es) 2022-02-28
MY178137A (en) 2020-10-05
PL3616706T3 (pl) 2022-02-07
LT3626731T (lt) 2022-02-10
ES2887107T3 (es) 2021-12-21
HRP20211580T1 (hr) 2022-01-21
CY1124846T1 (el) 2022-11-25
JP2020191873A (ja) 2020-12-03
JP7346361B2 (ja) 2023-09-19
ES2763911T3 (es) 2020-06-01
ZA201701762B (en) 2018-05-30
HRP20192212T1 (hr) 2020-03-20
SI3616706T1 (sl) 2021-12-31
CY1122491T1 (el) 2020-10-14
AU2022268329A1 (en) 2023-02-02
JP2020191866A (ja) 2020-12-03
JP2020191865A (ja) 2020-12-03
JP7448423B2 (ja) 2024-03-12
TWI794679B (zh) 2023-03-01
US20220016227A1 (en) 2022-01-20
MD3616706T2 (ro) 2022-01-31
CL2021001479A1 (es) 2022-02-04
MX2020011794A (es) 2020-12-07
SG10202102698VA (en) 2021-04-29
MX2020011793A (es) 2020-12-07
US20230031307A1 (en) 2023-02-02
PL3626729T3 (pl) 2022-02-21
HUE056087T2 (hu) 2022-01-28
US11672848B2 (en) 2023-06-13
MA49155A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
IL250989A0 (en) New peptides and a combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other types of cancer
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201505305D0 (en) Novel Peptides and combination of peptides for use in immunotherapy against various tumors
HK1246181A1 (zh) 用於各種腫瘤免疫治療的新型肽和肽組合物
HK1255541A1 (zh) 用於多種癌症免疫治療的新型肽和肽組合物
IL281752A (en) New peptides and combinations of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers